Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction
| Autor: | Hongwei Zhang, Juan Wang, Yunwei Han, Pan Zhou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research Blood transfusion Cancer cells MDSCs myeloid-derived suppressor cells medicine.medical_treatment EMT epithelial to mesenchymal transition Review P-EVs platelet-derived extracellular vesicles PDGF platelet-derived growth factor Metastasis sITP secondary immune-mediated thrombocytopenia 0302 clinical medicine CCDD cell combination drug delivery bFGF basic fibroblast growth factor TPO Thrombopoietin Platelet 5-HT 5-hydroxytryptamine PMP platelet microparticles rhTPO recombinant human thrombopoietin CTCs circulating tumor cells lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens VEGF vascular endothelial growth factor TNFα tumor necrosis factor α Cancer secondary thrombocytopenia FAK focal adhesion kinase 030220 oncology & carcinogenesis S1P sphingosine 1-phosphate PI3K phosphoinositide 3-kinase Platelets medicine.medical_specialty IL-1 Interleukin-1 ICH intracranial hemorrhage TA-GVHD transfusion-associated graft versus host disease lcsh:RC254-282 PD-1 programmed cell death protein 1 03 medical and health sciences TCIPA tumor cell induced platelet aggregation Internal medicine medicine PGE2 prostaglandin E2 GARP Glycoprotein A repetitions predominant Platelet activation IL-6 Interleukin-6 Survival rate business.industry PD-L1 programmed death-1 ligand IL-3 Interleukin-3 HSCs hematopoietic stem cells Cancer CLEC-2 C-type lectin-like receptor-2 pITP primary immune-mediated thrombocytopenia medicine.disease TGF-b transforming growth factor b CIT chemotherapy-induced thrombocytopenia 030104 developmental biology Platelet transfusion Cancer cell TF tissue factor Cox-2 cyclooxygenase 2 MMPs matrix metalloproteinases Lpa lysophosphatidic acid ITP immune thrombocytopenia business MAPK mitogen-activated protein kinase |
| Zdroj: | Translational Oncology, Vol 14, Iss 4, Pp 101022-(2021) Translational Oncology |
| ISSN: | 1936-5233 |
| Popis: | Highlights • Chemotherapy, radiotherapy and autoimmune disorder can cause thrombocytopenia in cancer patients. • The implications of platelet transfusion on cancer progression; a “vicious circle”. • Mechanisms and signaling pathways of tumor cell-induced platelet activation. • The strategies and windows of opportunities of platelet transfusion in cancer patients. Chemoradiotherapy and autoimmune disorder often lead to secondary thrombocytopenia in cancer patients, and thus, platelet transfusion is needed to stop or prevent bleeding. However, the effect of platelet transfusion remains controversial for the lack of agreement on transfusion strategies. Before being transfused, platelets are stored in blood banks, and their activation is usually stimulated. Increasing evidence shows activated platelets may promote metastasis and the proliferation of cancer cells, while cancer cells also induce platelet activation. Such a vicious cycle of interaction between activated platelets and cancer cells is harmful for the prognosis of cancer patients, which results in an increased tumor recurrence rate and decreased five-year survival rate. Therefore, it is important to explore platelet transfusion strategies, summarize mechanisms of interaction between platelets and tumor cells, and carefully evaluate the pros and cons of platelet transfusion for better treatment and prognosis for patients with cancer with secondary thrombocytopenia. Graphical abstract Activated platelets further promote tumor cell growth and platelet-derived extracellular vesicles promote tumor angiogenesis. Image, graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|